The TESCREAL bundle: Eugenics and the promise of utopia through artificial general intelligence
By Timnit Gebru and Émile P. Torres,
First Monday
| 04. 14. 2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can and should be built, researchers are working to create “safe AGI” that is “beneficial for all of humanity.” We argue that, unlike systems with specific applications which can be evaluated following standard engineering principles, undefined systems like “AGI” cannot be appropriately tested for safety. Why, then, is building AGI often framed as an unquestioned goal in the field of AI? In this paper, we argue that the normative framework that motivates much of this goal is rooted in the Anglo-American eugenics tradition of the twentieth century. As a result, many of the very same discriminatory attitudes that animated eugenicists in the past (e.g., racism, xenophobia, classism, ableism, and sexism) remain widespread within the movement to build AGI, resulting in systems that harm marginalized groups and centralize power, while using the language of “safety” and “benefiting humanity” to evade...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...